Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Both tirzepatide and semaglutide are GLP-1 receptor agonists that have transformed weight loss medicine. They work similarly but have key differences that matter for choosing between them.
How They Work
Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist — it mimics the GLP-1 hormone that regulates blood sugar and appetite. Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist — it activates both GLP-1 and GIP receptors, which may explain its stronger average weight loss effect. GIP is another incretin hormone involved in insulin secretion and fat metabolism.
Head-to-Head: Weight Loss Comparison
| Factor | Semaglutide 2.4mg | Tirzepatide 15mg |
|---|---|---|
| Avg weight loss (trial) | ~15% body weight | ~20–22% body weight |
| Mechanism | GLP-1 agonist | Dual GLP-1 + GIP |
| Brand name (weight) | Wegovy | Zepbound |
| Brand name (diabetes) | Ozempic | Mounjaro |
| Brand cost (no insurance) | $900–$1,400/mo | $900–$1,300/mo |
| Compounded available? | Yes — from $149/mo | Limited availability |
| Years of real-world data | More established | Newer |
The SURMOUNT-5 Trial: Direct Comparison
The landmark SURMOUNT-5 trial directly compared tirzepatide and semaglutide head-to-head in people with obesity. Tirzepatide 15mg produced approximately 47% more body weight reduction than semaglutide 2.4mg. However, both drugs produced meaningful and clinically significant weight loss — semaglutide users still lost an average of roughly 13–15% of body weight.
Side Effect Comparison
Both medications share similar GI side effects — nausea, vomiting, diarrhea, constipation — most common during dose escalation. Tirzepatide may cause slightly more nausea at higher doses in some people, though tolerability profiles are broadly similar. Neither should be used in people with personal or family history of medullary thyroid carcinoma or MEN2.
Which Should You Choose?
Choose tirzepatide if: you want maximum weight loss and your insurance covers it or you can access it affordably, you have not responded well enough to semaglutide, or your physician specifically recommends it for your metabolic profile.
Choose semaglutide if: you want the more established long-term safety record, you need a compounded/affordable option (compounded tirzepatide is much harder to find), or semaglutide alone achieves your goals — for many people it will.
The Practical Reality in 2026
Tirzepatide is slightly more effective on average. Semaglutide is far more accessible — especially via compounded telehealth programs that start around $149/month. For people without generous insurance coverage, compounded semaglutide delivers outstanding results at a price point that makes long-term treatment sustainable.
📖 Further Reading
- Zepbound vs Mounjaro — full comparison
- Cheapest way to get semaglutide in 2026
- semaglutide timeline results
- Mounjaro vs Wegovy — brand-level comparison
- Managing Ozempic nausea — complete guide
- Best Semaglutide for Weight Loss in 2026: Ranked & Reviewed
- How Much Weight Can You Lose on Semaglutide? (2026 Data)
Frequently Asked Questions
Q: Which is better for weight loss — tirzepatide or semaglutide?
A: Tirzepatide (Mounjaro/Zepbound) produces slightly more weight loss on average — about 20–22% body weight vs 15% for semaglutide at maximum doses. However semaglutide is far more accessible via compounded telehealth programs from $149/month, while brand tirzepatide costs $900–$1,300/month and has very limited compounded availability.
Q: Can I switch from semaglutide to tirzepatide?
A: Yes, with physician guidance. Some people who plateau on semaglutide switch to tirzepatide for additional weight loss. Your doctor can advise on an appropriate washout period and starting dose for the transition.
Q: Is tirzepatide FDA approved for weight loss?
A: Yes. Tirzepatide is FDA-approved as Zepbound for chronic weight management (obesity or overweight with at least one weight-related condition) and as Mounjaro for type 2 diabetes management.
Ready to Start? Access Compounded Semaglutide Online
Physician-supervised compounded semaglutide from $149/month. No insurance required.
Sponsored | Affiliate link
Affiliate disclosure: This article contains affiliate links. See our Affiliate Disclosure.
For more details, see our Mounjaro pricing breakdown.
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.